Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XERS Xeris Pharmaceuticals Inc

Closed Good Friday 04-17 16:00:00 EDT

4.11

+0.03

+0.74%

盘后4.10

-0.01-0.24%

18:02 EDT

High4.20	Low4.04	Vol1.91M
Open4.08	D1 Closing4.08	Amplitude3.92%
Mkt Cap632.69M	Tradable Cap602.76M	Total Shares153.94M
T/O7.86M	T/O Rate1.30%	Tradable Shares146.66M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"XERS","market":"US","secType":"STK","nameCN":"Xeris Pharmaceuticals Inc","latestPrice":4.11,"timestamp":1744920000000,"preClose":4.08,"halted":0,"volume":1906647,"hourTrading":{"tag":"盘后","latestPrice":4.1001,"preClose":4.11,"latestTime":"18:02 EDT","volume":19742,"amount":81139.3102,"timestamp":1744927329823},"delay":0,"floatShares":146657719,"shares":153940135,"eps":-0.373611,"marketStatus":"Closed Good Friday","change":0.03,"latestTime":"04-17 16:00:00 EDT","open":4.08,"high":4.2,"low":4.04,"amount":7858946.6846019,"amplitude":0.039216,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.373611,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1529553600000,"exchange":"NASDAQ","adjPreClose":4.08,"preHourTrading":{"tag":"盘前","latestPrice":4.1,"preClose":4.08,"latestTime":"09:22 EDT","volume":4160,"amount":16916.359200000003,"timestamp":1744896160669},"postHourTrading":{"tag":"盘后","latestPrice":4.1001,"preClose":4.11,"latestTime":"18:02 EDT","volume":19742,"amount":81139.3102,"timestamp":1744927329823},"volumeRatio":0.7480468416085548,"impliedVol":1.8608,"impliedVolPercentile":0.9482},"requestUrl":"/m/hq/s/XERS","defaultTab":"news","newsList":[{"id":"2522795345","title":"BRIEF-Xeris Announces Changes To Its Board Of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522795345","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522795345?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 20:39","pubTimestamp":1743165576,"startTime":"0","endTime":"0","summary":"BRIEF-Xeris Announces Changes To Its Board Of DirectorsMarch 28 (Reuters) - Xeris Biopharma Holdings Inc XERS.O:XERIS ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORSSource text: ID:nBw25fJYzaFurther company coverage: XERS.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nTUA7J9SMB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2522573642","title":"Xeris Announces Changes to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522573642","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522573642?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 20:00","pubTimestamp":1743163200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nTUA7J9SMB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2522058819","title":"Is Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5?","url":"https://stock-news.laohu8.com/highlight/detail?id=2522058819","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522058819?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 22:18","pubTimestamp":1743085124,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Xeris Biopharma Holdings, Inc.  stands against other hot biotech stocks under $5.A major factor in this upturn is the expected change in the Federal Reserve’s interest rate policies. Biotech needs lots of capital for expensive R&D and clinical tests, making it sensitive to shifting rate trends.Genetic Engineering and Biotechnology Newsnoted that lower rates increase capital availability, helping biotech companies extend operations, attract venture funds, and speed up drug development. Analysts think a rate cut could free up billions in sidelined investment money for struggling new biotech companies seeking stable funding.To identify the 10 Hot Biotech Stocks Under $5, we screened for companies in the biotechnology sector trading below $5 per share while meeting key financial and growth criteria. We focused on stocks with a strong market capitalization, ensuring they had","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xeris-biopharma-holdings-xers-hot-141844604.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USAW.SI","BK4007","QLD","QID","TSYW.SI","TQQQ","SQQQ","USJW.SI","XERS","MNQmain",".IXIC","NQmain","NVIW.SI","PSQ"],"gpt_icon":1},{"id":"2521783300","title":"Don't Ignore The Insider Selling In Xeris Biopharma Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2521783300","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521783300?lang=en_us&edition=full_marsco","pubTime":"2025-03-23 21:11","pubTimestamp":1742735494,"startTime":"0","endTime":"0","summary":"Anyone interested in Xeris Biopharma Holdings, Inc. ( NASDAQ:XERS ) should probably be aware that the Chief Legal...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/dont-ignore-the-insider-selling-in-xeris-biopharma-holdings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2520466167","title":"Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?","url":"https://stock-news.laohu8.com/highlight/detail?id=2520466167","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520466167?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 22:13","pubTimestamp":1742479980,"startTime":"0","endTime":"0","summary":"Xeris Biopharma  shares ended the last trading session 5.6% higher at $5.51. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 34.9% gain over the past four weeks.Earlier this week, the FDA approved Xeris’ supplemental new drug application for Gvoke VialDx for use as a diagnostic aid, designed to temporarily inhibit movement of the gastrointestinal tract in adult patients during radiologic diagnostic procedures. The company also entered into a partnership with American Regent to commercialize Gvoke VialDx in the United States. The growing optimism related to this development might have driven the recent share price rally.This company is expected to post quarterly loss of $0.07 per share in its upcoming report, which represents a year-over-year change of +50%. Revenues are expected to be $57.75 million, up 42.1% from the year-ago quarter.Earnings and revenue growth expectations certainly give a g","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/strength-seen-xeris-biopharma-xers-141300549.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AUPH","BK4007","XERS","BK4139"],"gpt_icon":0},{"id":"2520231475","title":"Xeris Biopharma Says US FDA Approves Gvoke VialDx for Diagnostic Use","url":"https://stock-news.laohu8.com/highlight/detail?id=2520231475","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520231475?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 20:31","pubTimestamp":1742214702,"startTime":"0","endTime":"0","summary":"Xeris Biopharma (XERS) said Monday that the US Food and Drug Administration has approved the company's supplemental new drug application for Gvoke VialDx for use as a diagnostic aid to temporarily inh","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2520528147","title":"Xeris Biopharma Holdings Inc - Gvoke Vialdx Expected to Be Available in Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520528147","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520528147?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 20:00","pubTimestamp":1742212804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nTUAC6DF1G:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2520540877","title":"Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid","url":"https://stock-news.laohu8.com/highlight/detail?id=2520540877","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520540877?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 20:00","pubTimestamp":1742212800,"startTime":"0","endTime":"0","summary":"First concentrated, ready-to-dilute liquid glucagon available for growing procedural gastroenterology market. Availability is expected in the third quarter of 2025. CHICAGO, March 17, 2025----Xeris Biopharma Holdings, Inc. , a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that its supplemental new drug application  of Gvoke VialDx has received U.S Food and Drug Administration  approval for use as a diagnostic aid during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients.Xeris also announced it has partnered with American Regent to commercialize Gvoke VialDx. Under the terms of the agreement, Xeris will be responsible for product supply, and American Regent will be responsible for the commercialization of Gvoke VialDx in the U.S. Financial terms were not disclosed.Gvoke VialDx is also contraindicated in p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xeris-announces-approval-supplemental-drug-120000486.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2518524203","title":"Xeris Biopharma Is Maintained at Buy by Craig-Hallum","url":"https://stock-news.laohu8.com/highlight/detail?id=2518524203","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518524203?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 19:21","pubTimestamp":1741605660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XERS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 10, 2025 07:21 ET (11:21 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS"],"gpt_icon":0},{"id":"2517461639","title":"Xeris Biopharma price target raised to $6 from $5 at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2517461639","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517461639?lang=en_us&edition=full_marsco","pubTime":"2025-03-08 06:05","pubTimestamp":1741385142,"startTime":"0","endTime":"0","summary":"Leerink analyst Roanna Ruiz raised the firm’s price target on Xeris Biopharma (XERS) to $6 from $5 and keeps an Outperform rating on the shares. Pu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xeris-biopharma-price-target-raised-to-6-from-5-at-leerink?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xeris-biopharma-price-target-raised-to-6-from-5-at-leerink?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"1170376919","title":"Stock Track | Xeris Pharmaceuticals Soars 5.33% as Analysts Raise Price Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=1170376919","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170376919?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 22:48","pubTimestamp":1741358895,"startTime":"0","endTime":"0","summary":"Shares of Xeris Pharmaceuticals Inc  soared 5.33% in the pre-market session on Friday, following analysts raising their price targets on the stock.Piper Sandler raised its price target on Xeris Biopharma to $4 from $3, while maintaining a Neutral rating. H.C. Wainwright also boosted its price target to $8 from $6.60 and reiterated a Buy rating on the shares.The positive analyst actions reflect optimism around Xeris Pharmaceuticals' prospects, driving the stock's significant upward movement durin","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Xeris Pharmaceuticals Soars 5.33% as Analysts Raise Price Targets","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["XERS"],"gpt_icon":0},{"id":"2517484536","title":"Xeris Biopharma price target raised to $4 from $3 at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2517484536","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517484536?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 20:08","pubTimestamp":1741349295,"startTime":"0","endTime":"0","summary":"Piper Sandler raised the firm’s price target on Xeris Biopharma (XERS) to $4 from $3 and keeps a Neutral rating on the shares. The firm notes Xeris...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xeris-biopharma-price-target-raised-to-4-from-3-at-piper-sandler?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xeris-biopharma-price-target-raised-to-4-from-3-at-piper-sandler?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2517481364","title":"Xeris Biopharma Price Target Raised to $8.00/Share From $6.60 by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2517481364","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517481364?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 20:00","pubTimestamp":1741348800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XERS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 07, 2025 07:00 ET (12:00 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS"],"gpt_icon":0},{"id":"2517485154","title":"Xeris Biopharma price target raised to $8 from $6.60 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2517485154","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517485154?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 19:11","pubTimestamp":1741345871,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Oren Livnat raised the firm’s price target on Xeris Biopharma (XERS) to $8 from $6.60 and keeps a Buy rating on the shares....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xeris-biopharma-price-target-raised-to-8-from-6-60-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xeris-biopharma-price-target-raised-to-8-from-6-60-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2517171494","title":"Xeris Biopharma Holdings Inc (XERS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2517171494","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517171494?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 15:08","pubTimestamp":1741331313,"startTime":"0","endTime":"0","summary":"For the complete transcript of the earnings call, please refer to the full earnings call transcript.Xeris Biopharma Holdings Inc  exceeded its full-year guidance with total revenue of over $203 million, marking a 24% growth compared to the previous year.The company reported a 28% product revenue growth for 2024, driven by strong demand for its products, particularly Recole, which saw a 118% increase in revenue.The company is guiding for a 30% year-over-year revenue growth in 2025, with expected total revenue between $255 and $275 million.Caveyas brand experienced a 13% decline in revenue for the full year, although the number of patients on therapy remained stable.The company anticipates continued pressure on reimbursement and net pricing for its products, similar to what was experienced in 2024.Selling, general, and administrative expenses rose by 12% for the year, partly due to a one-time charge related to CEO succession and corporate restructuring.GuruFocus has detected 7 Warning Si","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xeris-biopharma-holdings-inc-xers-070833798.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["XERS"],"gpt_icon":0},{"id":"2517116458","title":"Xeris Biopharma files $250M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2517116458","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517116458?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 05:55","pubTimestamp":1741298133,"startTime":"0","endTime":"0","summary":"16:54 EST Xeris Biopharma (XERS) files $250M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving br...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xeris-biopharma-files-250m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xeris-biopharma-files-250m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2517519323","title":"Xeris Biopharma Shares Rise on Expectation of Significant Full-Year Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2517519323","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517519323?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 01:10","pubTimestamp":1741281000,"startTime":"0","endTime":"0","summary":"Shares of Xeris Biopharma climbed after the company guided for higher revenue in 2025.The stock was up 17%, to $4.41, in Thursday trading, which is equivalent to the highest close since June 28, 2021. Shares have plunged 81% over the past 12 months.The biopharmaceutical company projected full-year revenue of $255 million to $275 million, representing growth of over 30% at the mid-point range.The Chicago company also expects adjusted earnings before interest, taxes, depreciation and amortization to remain positive going forward, Finance Chief Steven Pieper said.\"Our accelerating revenue growth, coupled with our attractive and improving margin profile and disciplined capital allocation, will result in a financially transformative 2025 for Xeris,\" Pieper said.The company's outlook came as it reported a significant increase in product revenue in the fourth quarter.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS"],"gpt_icon":0},{"id":"1160213805","title":"Stock Track | Xeris Pharmaceuticals Soars 9.81% on Record Q4 Results and Strong 2025 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1160213805","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160213805?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 22:36","pubTimestamp":1741271798,"startTime":"0","endTime":"0","summary":"Xeris Pharmaceuticals Inc  saw its stock soar 9.81% in the pre-market session on Thursday, following the release of its outstanding fourth quarter and full-year 2024 financial results, along with robust revenue guidance for 2025.The biopharmaceutical company reported record total revenue of $60.1 million for the fourth quarter, representing a substantial 35.4% increase year-over-year. This impressive growth was driven by strong sales of its key products, Gvoke and Recorlev. Gvoke, a ready-to-use","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["XERS"],"gpt_icon":0},{"id":"2517268163","title":"Xeris Biopharma Holdings Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2517268163","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517268163?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 22:32","pubTimestamp":1741271526,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Holdings Inc reports results for the quarter ended December 31 - Earnings SummaryXeris Biopharma Holdings Inc XERS.OQ reported a quarterly adjusted loss of 3 cents per share for the qu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nL5N3PP1HY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS"],"gpt_icon":0},{"id":"2517195028","title":"Here's What Key Metrics Tell Us About Xeris Biopharma (XERS) Q4 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2517195028","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517195028?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 22:30","pubTimestamp":1741271406,"startTime":"0","endTime":"0","summary":"Xeris Biopharma  reported $60.1 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 35.4%. EPS of -$0.03 for the same period compares to -$0.10 a year ago.The reported revenue represents a surprise of -0.81% over the Zacks Consensus Estimate of $60.59 million. With the consensus EPS estimate being -$0.07, the EPS surprise was +57.14%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Here is how Xeris Biopharma performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:. Product Revenue- Gvoke: $23.26 million compared to the $23.90 million average estimate based on five analysts.Product Revenue- Keveyis: $11.12 million compared to the $21.19 million ave","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-key-metrics-tell-us-143006707.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["XERS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xerispharma.com","stockEarnings":[{"period":"1week","weight":0.0405},{"period":"1month","weight":-0.2126},{"period":"3month","weight":0.2844},{"period":"6month","weight":0.3431},{"period":"1year","weight":1.309},{"period":"ytd","weight":0.2124}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.071149},{"month":2,"riseRate":0.714286,"avgChangeRate":-0.011486},{"month":3,"riseRate":0.571429,"avgChangeRate":-0.030403},{"month":4,"riseRate":0.428571,"avgChangeRate":0.018556},{"month":5,"riseRate":0.666667,"avgChangeRate":0.186811},{"month":6,"riseRate":0.5,"avgChangeRate":-0.069518},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.024057},{"month":8,"riseRate":0.571429,"avgChangeRate":0.160809},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.078859},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.032117},{"month":11,"riseRate":0.571429,"avgChangeRate":0.00843},{"month":12,"riseRate":0.571429,"avgChangeRate":0.04577}],"exchange":"NASDAQ","name":"Xeris Pharmaceuticals Inc","nameEN":"Xeris Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Xeris Pharmaceuticals Inc(XERS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Xeris Pharmaceuticals Inc,XERS,Xeris Pharmaceuticals Inc股票,Xeris Pharmaceuticals Inc股票老虎,Xeris Pharmaceuticals Inc股票老虎国际,Xeris Pharmaceuticals Inc行情,Xeris Pharmaceuticals Inc股票行情,Xeris Pharmaceuticals Inc股价,Xeris Pharmaceuticals Inc股市,Xeris Pharmaceuticals Inc股票价格,Xeris Pharmaceuticals Inc股票交易,Xeris Pharmaceuticals Inc股票购买,Xeris Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Xeris Pharmaceuticals Inc(XERS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction